Loading patent…
AssigneePfizer Inc.
InventorsPhilip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki
Estimating the term…
The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs:
A polynucleotide encoding a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID Nos:
A composition comprising a polynucleotide encoding a polypeptide comprising the sequence selected from any one of SEQ ID Nos:
A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a polypeptide comprising the sequence set forth in any one of SEQ ID Nos:
A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a polynucleotide encoding a polypeptide comprising the sequence set forth in any one of SEQ ID Nos:
Dependencies are inferred from the claim text.